To further explore the potential role of ceramides in renal pathophysiology, while controlling for the genetic and environmental heterogeneity inherent in human subject research, we studied a rodent model in which renal triglyceride accumulation has been linked with surrogate functional markers of uric acid stone risk, including data showing that reduction of triglyceride accumulation with a PPARγ agonist reversed the functional defects [18], [19]. This evidence concerns the gene PPARG and Uric acid nephrolithiasis.